Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

The effect of LongoVital … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The effect of LongoVital on recurrent aphthous stomatitis in a controlled clinical trial.

Artikel i vetenskaplig tidskrift
Författare John Bratel
Magnus Hakeberg
Mats Jontell
Publicerad i Oral health & preventive dentistry
Volym 3
Nummer/häfte 1
Sidor 3-8
ISSN 1602-1622
Publiceringsår 2005
Publicerad vid Odontologiska institutionen
Sidor 3-8
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Phytotherapy, Plant Components, Plant Preparations, therapeutic use, Plants, Medicinal, Recurrence, prevention & control, Statistics, Nonparametric, Stomatitis, Aphthous, prevention & control, Tablets, Vitamins, therapeutic use
Ämneskategorier Odontologi, Övrig odontologi

Sammanfattning

PURPOSE: The aim of this study was to evaluate the effect of daily intake of LongoVital (LV) (herbal vitamin tablets) in the prevention of RAS. MATERIALS AND METHODS: A group of 78 consecutively referred patients was enrolled to a three-months pretreatment period. Fifty subjects were then randomly allocated to an LV-group (n = 25) or a placebo group (N = 25). A double blind, stratified-randomised clinical case-control study was performed during six months. Number and size of the ulcers were registered by the patients using a standardized chart. The degree of discomfort was recorded on a 100 mm horizontal visual analogue scale (VAS-scale). RESULTS: The three-months pretreatment period revealed that the most dominant symptoms were pain (78%) followed by burning sensation (18%). No significant differences between the two groups were found during this period when a comparison was made at the end of the study. After the intervention period the number of aphthous ulcers/month decreased significantly in the LV-group (p = 0.02). The number of days in pain/month were also reduced (p < 0.001). If a 50% reduction of number of aphthous ulcers and days in pain were considered as clinically relevant, no statistical significant differences were found between the groups. CONCLUSION: Thus, no strong evidence was found that justified a recommendation of LV as a general drug for treatment of RAS.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?publicationId=55369
Utskriftsdatum: 2020-08-09